At Jubilant Pharma, we are focused towards APIs production for Cardiovascular System (CVS) and Central Nervous System (CNS) therapeutic areas besides few Anti-infective, Analgesic, and Antispasmodic.
We are global exporters in APIs and continue to build on our previous track records by developing our cost competitiveness through implementation of:
• Proficient manufacturing processes and systems
• Accelerating Drug Master File (DMF) filings
• Entering into and expanding relationships with major US, European and Indian generic companies for sale of our APIs
• Increasing our APIs product portfolio by setting our foot first in the markets
Jubilant Pharma is a prominent presence in markets across the globe such as North America, South America, Europe, Japan, Korea, Commonwealth of Independent States (CIS) countries, the Middle East and Australia. Our API customers are leading global generic companies.
Our APIs facility at Nanjangud, Karnataka, India is a USFDA, Japan PMDA, UK MHRA and Brazil ANVISA audited and approved site. This modern, fully equipped and GMP approved manufacturing facility has Comprehensive Effluent management systems to make facility a Zero Discharge Site
We have some of the world’s largest capacities of APIs such as Carbamazepine, Oxcarbazepine, Citalopram, Lamotrigine, Donepezil, Pinaverium Bromide, Meclizine, Escitalopram and Azithromycin Monohydrate are the most significant ones. We ensure that all our plant lines endow with the desired turnover, with least possible downtime and maximum optimal product mix.
Our focus in API Research is to develop cost effective / commercially viable, non-infringing, eco-friendly / safe technologies and select appropriate polymorph(s) for Active Pharmaceutical Ingredients (APIs) to support API Business, In-House ANDA Programs. The thrust is to create greater value addition through developing innovative process know-hows. A team of dedicated scientists are working in the areas of Process Chemistry Research, Analytical Research & IP Management Group in R&D centre which conforms to International Standards and is recognized by the Department of Science & Technology, Govt. of India.
We are optimising and de-bottlenecking all our operations to tap most of the opportunities and counter the challenges that arise due to the increased demands. Our future development is going to be driven by our strategic objective of focussing and specialising in certain therapeutic areas and integrating vertically to the formulation development.